Share Price and Basic Stock Data
Last Updated: October 28, 2025, 2:23 pm
| PEG Ratio | 0.15 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lupin Ltd, a prominent player in the pharmaceuticals sector, reported a market capitalization of ₹88,716 Cr, with its share price standing at ₹1,942. The company’s revenue from operations showed a robust upward trend, with TTM sales reaching ₹23,376 Cr, reflecting a significant increase from ₹22,708 Cr in FY 2025. Quarterly sales figures depict consistent growth, with the most recent quarter (Jun 2025) recording sales of ₹6,268 Cr, up from ₹5,600 Cr in the previous quarter. This consistent revenue growth, particularly in the last four quarters, underscores the company’s effective operational strategies and market positioning. Notably, the operating profit margin (OPM) improved to 28% in Jun 2025, indicating enhanced operational efficiency. Such performance is indicative of Lupin’s strong footing in the competitive pharmaceutical landscape, where it continues to capitalize on emerging market opportunities.
Profitability and Efficiency Metrics
Lupin’s profitability metrics have shown remarkable recovery and improvement over the fiscal year. The net profit for FY 2025 stood at ₹3,306 Cr, a substantial increase from ₹448 Cr in FY 2023, demonstrating the company’s effective cost management and operational efficiencies. The earnings per share (EPS) also reflected this upward trajectory, rising to ₹71.95 in FY 2025, compared to ₹9.46 in FY 2023. The company’s return on equity (ROE) was recorded at 20.6%, while return on capital employed (ROCE) stood at 21.3%, both of which are favorable compared to sector averages. Furthermore, the interest coverage ratio (ICR) of 18.58x signifies strong earnings relative to interest obligations, showcasing financial stability. However, the cash conversion cycle (CCC) of 223 days indicates areas where working capital management could improve, especially when compared to industry benchmarks.
Balance Sheet Strength and Financial Ratios
Lupin’s balance sheet exhibits solid financial health, with total assets amounting to ₹28,978 Cr and reserves of ₹17,112 Cr. The company’s borrowings increased to ₹5,448 Cr, reflecting a strategic approach to leverage for growth opportunities. The debt-to-equity ratio stood at 0.29, suggesting a manageable level of debt relative to equity, which is favorable compared to typical sector norms. Additionally, the current ratio of 1.87 indicates adequate liquidity to meet short-term liabilities, while the quick ratio of 1.26 further confirms financial resilience. The price-to-book value (P/BV) ratio of 5.38x reflects investor confidence, although it is higher than the industry average, potentially indicating overvaluation concerns. Overall, Lupin’s financial ratios suggest a well-capitalized firm capable of navigating market fluctuations effectively.
Shareholding Pattern and Investor Confidence
The shareholding structure of Lupin Ltd reveals a diverse ownership base, with promoters holding 46.90% of the shares, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 21.25% and 25.55%, respectively. This distribution indicates a balanced mix of domestic and foreign investment, fostering investor confidence. However, the gradual decline in promoter holdings from 47.11% in Sep 2022 to 46.90% in Mar 2025 may raise concerns regarding long-term commitment. Additionally, the number of shareholders has shown a slight decrease, from 3,78,011 in Sep 2022 to 2,86,604 in Jun 2025, which could signal a consolidation of ownership or a shift in investor sentiment. The presence of institutional investors indicates a level of confidence in Lupin’s strategic direction and financial performance, which is critical for future fundraising and market positioning.
Outlook, Risks, and Final Insight
Lupin Ltd is positioned for continued growth, driven by its strong revenue trajectory and improved profitability metrics. However, potential risks include increasing competition in the pharmaceutical sector and regulatory challenges, which could impact margins and market share. Additionally, the high cash conversion cycle may hinder liquidity in times of operational stress. Should the company successfully address these operational challenges while maintaining its growth momentum, it has the potential to enhance shareholder value significantly. Conversely, failure to navigate competitive pressures and manage costs effectively could pose substantial risks to its financial performance. Overall, Lupin’s strategic initiatives and robust financial health provide a solid foundation for navigating the complexities of the pharmaceutical industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lupin Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,766.58 Cr | 1,179.77 | 50.40 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,744 | 4,146 | 4,322 | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 |
| Expenses | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 |
| Operating Profit | 232 | 453 | 533 | 578 | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 |
| OPM % | 6% | 11% | 12% | 13% | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% |
| Other Income | 6 | 15 | 18 | 37 | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 |
| Interest | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 |
| Depreciation | 193 | 203 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 |
| Profit before tax | 2 | 210 | 246 | 258 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 |
| Tax % | 3,925% | 36% | 36% | 6% | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% |
| Net Profit | -87 | 134 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 |
| EPS in Rs | -1.96 | 2.85 | 3.37 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 |
Last Updated: August 20, 2025, 7:40 am
Below is a detailed analysis of the quarterly data for Lupin Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,667.00 Cr. (Mar 2025) to 6,268.00 Cr., marking an increase of 601.00 Cr..
- For Expenses, as of Jun 2025, the value is 4,541.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,346.00 Cr. (Mar 2025) to 4,541.00 Cr., marking an increase of 195.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1,727.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,321.00 Cr. (Mar 2025) to 1,727.00 Cr., marking an increase of 406.00 Cr..
- For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 28.00%, marking an increase of 5.00%.
- For Other Income, as of Jun 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 22.00 Cr..
- For Interest, as of Jun 2025, the value is 92.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 89.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 299.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 393.00 Cr. (Mar 2025) to 299.00 Cr., marking a decrease of 94.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 1,416.00 Cr.. The value appears strong and on an upward trend. It has increased from 896.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 520.00 Cr..
- For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 14.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 1,221.00 Cr.. The value appears strong and on an upward trend. It has increased from 782.00 Cr. (Mar 2025) to 1,221.00 Cr., marking an increase of 439.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 26.69. The value appears strong and on an upward trend. It has increased from 16.92 (Mar 2025) to 26.69, marking an increase of 9.77.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:56 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 23,376 |
| Expenses | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 17,631 |
| Operating Profit | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 5,745 |
| OPM % | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 19% | 23% | 25% |
| Other Income | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 232 |
| Interest | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 319 |
| Depreciation | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,221 |
| Profit before tax | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 4,438 |
| Tax % | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | |
| Net Profit | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 3,722 |
| EPS in Rs | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 81.04 |
| Dividend Payout % | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.70% | -7.12% | 13.00% | -89.94% | 138.37% | -143.90% | 554.81% | -224.43% | 129.32% | 332.14% | 70.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -37.81% | 20.12% | -102.94% | 228.31% | -282.27% | 698.72% | -779.24% | 353.75% | 202.82% | -261.38% |
Lupin Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 55% |
| 3 Years: | 60% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 15% |
| 3 Years: | 44% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 13% |
| Last Year: | 21% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: July 25, 2025, 2:50 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 |
| Borrowings | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 2,922 | 5,448 |
| Other Liabilities | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,539 | 6,327 |
| Total Liabilities | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 |
| Fixed Assets | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 |
| CWIP | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 |
| Investments | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 |
| Other Assets | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 |
| Total Assets | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 |
Below is a detailed analysis of the balance sheet data for Lupin Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 91.00 Cr..
- For Reserves, as of Mar 2025, the value is 17,112.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,199.00 Cr. (Mar 2024) to 17,112.00 Cr., marking an increase of 2,913.00 Cr..
- For Borrowings, as of Mar 2025, the value is 5,448.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,922.00 Cr. (Mar 2024) to 5,448.00 Cr., marking an increase of 2,526.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 6,327.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,539.00 Cr. (Mar 2024) to 6,327.00 Cr., marking a decrease of 212.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 28,978.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23,751.00 Cr. (Mar 2024) to 28,978.00 Cr., marking an increase of 5,227.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 9,719.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,878.00 Cr. (Mar 2024) to 9,719.00 Cr., marking an increase of 841.00 Cr..
- For CWIP, as of Mar 2025, the value is 517.00 Cr.. The value appears to be declining and may need further review. It has decreased from 773.00 Cr. (Mar 2024) to 517.00 Cr., marking a decrease of 256.00 Cr..
- For Investments, as of Mar 2025, the value is 1,146.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,075.00 Cr. (Mar 2024) to 1,146.00 Cr., marking an increase of 71.00 Cr..
- For Other Assets, as of Mar 2025, the value is 17,596.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,026.00 Cr. (Mar 2024) to 17,596.00 Cr., marking an increase of 4,570.00 Cr..
- For Total Assets, as of Mar 2025, the value is 28,978.00 Cr.. The value appears strong and on an upward trend. It has increased from 23,751.00 Cr. (Mar 2024) to 28,978.00 Cr., marking an increase of 5,227.00 Cr..
Notably, the Reserves (17,112.00 Cr.) exceed the Borrowings (5,448.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -651.00 | -534.00 | -4.00 | -3.00 | -4.00 | -6.00 | -4.00 | -3.00 | 215.00 | -3.00 | 1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 |
| Inventory Days | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 |
| Days Payable | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 |
| Cash Conversion Cycle | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 |
| Working Capital Days | 81 | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 |
| ROCE % | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% | 16% | 21% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund - Regular Plan | 5,852,165 | 1.03 | 660.21 | 5,852,165 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Bluechip Fund | 5,051,556 | 1.38 | 569.89 | 5,051,556 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Value Discovery Fund | 4,451,818 | 1.55 | 502.23 | 4,451,818 | 2025-04-22 17:25:28 | 0% |
| HDFC Flexi Cap Fund - Regular Plan | 4,250,000 | 1.22 | 479.46 | 4,250,000 | 2025-04-22 17:25:28 | 0% |
| Mirae Asset Emerging Bluechip Fund | 4,055,585 | 1.63 | 457.53 | 4,055,585 | 2025-04-22 17:25:28 | 0% |
| HDFC Top 100 Fund - Regular Plan | 3,369,013 | 1.47 | 380.08 | 3,369,013 | 2025-04-22 12:29:18 | 0% |
| Mirae Asset Midcap Fund | 2,934,086 | 2.81 | 331.01 | 2,934,086 | 2025-04-22 17:25:28 | 0% |
| SBI Long Term Equity Fund | 2,687,887 | 1.92 | 303.23 | 2,687,887 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Multi Asset Fund | 2,004,292 | 0.91 | 226.11 | 2,004,292 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Large & Mid Cap Fund | 1,584,850 | 2.02 | 178.79 | 1,584,850 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 71.95 | 42.05 | 9.46 | -33.65 | 26.84 |
| Diluted EPS (Rs.) | 71.95 | 41.87 | 9.41 | -33.65 | 26.72 |
| Cash EPS (Rs.) | 98.02 | 68.74 | 29.20 | 3.28 | 46.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Revenue From Operations / Share (Rs.) | 497.33 | 439.12 | 365.75 | 360.96 | 334.21 |
| PBDIT / Share (Rs.) | 120.00 | 86.26 | 41.13 | 9.44 | 59.58 |
| PBIT / Share (Rs.) | 94.39 | 59.99 | 21.78 | -27.06 | 40.02 |
| PBT / Share (Rs.) | 87.93 | 53.15 | 15.75 | -30.20 | 36.92 |
| Net Profit / Share (Rs.) | 72.41 | 42.47 | 9.84 | -33.22 | 27.04 |
| NP After MI And SOA / Share (Rs.) | 71.87 | 42.01 | 9.45 | -33.62 | 26.81 |
| PBDIT Margin (%) | 24.12 | 19.64 | 11.24 | 2.61 | 17.82 |
| PBIT Margin (%) | 18.97 | 13.66 | 5.95 | -7.49 | 11.97 |
| PBT Margin (%) | 17.68 | 12.10 | 4.30 | -8.36 | 11.04 |
| Net Profit Margin (%) | 14.55 | 9.67 | 2.69 | -9.20 | 8.08 |
| NP After MI And SOA Margin (%) | 14.45 | 9.56 | 2.58 | -9.31 | 8.02 |
| Return on Networth / Equity (%) | 19.07 | 13.39 | 3.45 | -12.57 | 8.81 |
| Return on Capital Employeed (%) | 21.29 | 17.64 | 7.23 | -9.07 | 11.96 |
| Return On Assets (%) | 11.23 | 7.97 | 1.87 | -7.00 | 5.15 |
| Long Term Debt / Equity (X) | 0.10 | 0.00 | 0.00 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.29 | 0.18 | 0.34 | 0.31 | 0.22 |
| Asset Turnover Ratio (%) | 0.85 | 0.85 | 0.50 | 0.51 | 0.47 |
| Current Ratio (X) | 1.87 | 1.58 | 1.34 | 1.51 | 1.66 |
| Quick Ratio (X) | 1.26 | 0.99 | 0.85 | 0.94 | 1.17 |
| Inventory Turnover Ratio (X) | 4.35 | 0.87 | 0.82 | 0.77 | 0.88 |
| Dividend Payout Ratio (NP) (%) | 11.11 | 9.50 | 42.28 | -19.31 | 22.34 |
| Dividend Payout Ratio (CP) (%) | 8.19 | 5.85 | 13.87 | 225.82 | 12.92 |
| Earning Retention Ratio (%) | 88.89 | 90.50 | 57.72 | 119.31 | 77.66 |
| Cash Earning Retention Ratio (%) | 91.81 | 94.15 | 86.13 | -125.82 | 87.08 |
| Interest Coverage Ratio (X) | 18.58 | 12.61 | 6.82 | 3.00 | 19.22 |
| Interest Coverage Ratio (Post Tax) (X) | 12.21 | 7.21 | 2.63 | -9.57 | 9.72 |
| Enterprise Value (Cr.) | 94555.16 | 75275.95 | 32506.42 | 36722.71 | 47698.57 |
| EV / Net Operating Revenue (X) | 4.16 | 3.76 | 1.95 | 2.24 | 3.15 |
| EV / EBITDA (X) | 17.26 | 19.15 | 17.37 | 85.62 | 17.65 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| Retention Ratios (%) | 88.88 | 90.49 | 57.71 | 119.31 | 77.65 |
| Price / BV (X) | 5.38 | 5.16 | 2.36 | 2.79 | 3.36 |
| Price / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| EarningsYield | 0.03 | 0.02 | 0.01 | -0.04 | 0.02 |
After reviewing the key financial ratios for Lupin Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 42.05 (Mar 24) to 71.95, marking an increase of 29.90.
- For Diluted EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 41.87 (Mar 24) to 71.95, marking an increase of 30.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 98.02. This value is within the healthy range. It has increased from 68.74 (Mar 24) to 98.02, marking an increase of 29.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 497.33. It has increased from 439.12 (Mar 24) to 497.33, marking an increase of 58.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 120.00. This value is within the healthy range. It has increased from 86.26 (Mar 24) to 120.00, marking an increase of 33.74.
- For PBIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 59.99 (Mar 24) to 94.39, marking an increase of 34.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 87.93. This value is within the healthy range. It has increased from 53.15 (Mar 24) to 87.93, marking an increase of 34.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 72.41. This value is within the healthy range. It has increased from 42.47 (Mar 24) to 72.41, marking an increase of 29.94.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 71.87. This value is within the healthy range. It has increased from 42.01 (Mar 24) to 71.87, marking an increase of 29.86.
- For PBDIT Margin (%), as of Mar 25, the value is 24.12. This value is within the healthy range. It has increased from 19.64 (Mar 24) to 24.12, marking an increase of 4.48.
- For PBIT Margin (%), as of Mar 25, the value is 18.97. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 18.97, marking an increase of 5.31.
- For PBT Margin (%), as of Mar 25, the value is 17.68. This value is within the healthy range. It has increased from 12.10 (Mar 24) to 17.68, marking an increase of 5.58.
- For Net Profit Margin (%), as of Mar 25, the value is 14.55. This value exceeds the healthy maximum of 10. It has increased from 9.67 (Mar 24) to 14.55, marking an increase of 4.88.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.45. This value is within the healthy range. It has increased from 9.56 (Mar 24) to 14.45, marking an increase of 4.89.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.07. This value is within the healthy range. It has increased from 13.39 (Mar 24) to 19.07, marking an increase of 5.68.
- For Return on Capital Employeed (%), as of Mar 25, the value is 21.29. This value is within the healthy range. It has increased from 17.64 (Mar 24) to 21.29, marking an increase of 3.65.
- For Return On Assets (%), as of Mar 25, the value is 11.23. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.23, marking an increase of 3.26.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.10, marking an increase of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. There is no change compared to the previous period (Mar 24) which recorded 0.85.
- For Current Ratio (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 1.87, marking an increase of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has increased from 0.99 (Mar 24) to 1.26, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.35. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 4.35, marking an increase of 3.48.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.11. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 24) to 11.11, marking an increase of 1.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 20. It has increased from 5.85 (Mar 24) to 8.19, marking an increase of 2.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.89. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 24) to 88.89, marking a decrease of 1.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.81. This value exceeds the healthy maximum of 70. It has decreased from 94.15 (Mar 24) to 91.81, marking a decrease of 2.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.58. This value is within the healthy range. It has increased from 12.61 (Mar 24) to 18.58, marking an increase of 5.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.21. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 12.21, marking an increase of 5.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 94,555.16. It has increased from 75,275.95 (Mar 24) to 94,555.16, marking an increase of 19,279.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 3.76 (Mar 24) to 4.16, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.26. This value exceeds the healthy maximum of 15. It has decreased from 19.15 (Mar 24) to 17.26, marking a decrease of 1.89.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For Retention Ratios (%), as of Mar 25, the value is 88.88. This value exceeds the healthy maximum of 70. It has decreased from 90.49 (Mar 24) to 88.88, marking a decrease of 1.61.
- For Price / BV (X), as of Mar 25, the value is 5.38. This value exceeds the healthy maximum of 3. It has increased from 5.16 (Mar 24) to 5.38, marking an increase of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lupin Ltd:
- Net Profit Margin: 14.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 21.29% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.07% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.6 (Industry average Stock P/E: 50.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kalpataru Inspire, 3rd Floor, Mumbai Maharashtra 400055 | info@lupin.com http://www.lupin.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Manju D Gupta | Chairperson |
| Mr. Nilesh D Gupta | Managing Director |
| Ms. Vinita Gupta | Director & CEO |
| Mr. Ramesh Swaminathan | Executive Director & Global CFO |
| Mr. Mark D McDade | Independent Director |
| Dr. Punita Kumar-Sinha | Independent Director |
| Mr. Jean-Luc Belingard | Independent Director |
| Mr. Jeffrey Kindler | Independent Director |
| Mr. Alfonso Zulueta | Independent Director |
| Mr. K B S Anand | Independent Director |
| Mr. Punita Lal | Independent Director |
FAQ
What is the intrinsic value of Lupin Ltd?
Lupin Ltd's intrinsic value (as of 28 October 2025) is 1475.35 which is 22.64% lower the current market price of 1,907.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 87,113 Cr. market cap, FY2025-2026 high/low of 2,403/1,774, reserves of ₹17,112 Cr, and liabilities of 28,978 Cr.
What is the Market Cap of Lupin Ltd?
The Market Cap of Lupin Ltd is 87,113 Cr..
What is the current Stock Price of Lupin Ltd as on 28 October 2025?
The current stock price of Lupin Ltd as on 28 October 2025 is 1,907.
What is the High / Low of Lupin Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lupin Ltd stocks is 2,403/1,774.
What is the Stock P/E of Lupin Ltd?
The Stock P/E of Lupin Ltd is 23.6.
What is the Book Value of Lupin Ltd?
The Book Value of Lupin Ltd is 377.
What is the Dividend Yield of Lupin Ltd?
The Dividend Yield of Lupin Ltd is 0.62 %.
What is the ROCE of Lupin Ltd?
The ROCE of Lupin Ltd is 21.3 %.
What is the ROE of Lupin Ltd?
The ROE of Lupin Ltd is 20.6 %.
What is the Face Value of Lupin Ltd?
The Face Value of Lupin Ltd is 2.00.